However, despite these promising preclinical findings, the absence of head-to-head trials presents a gap in establishing definitive comparative clinical efficacy between lorlatinib and existing therapeutic options [8]. A recent network meta-analysis attempted to address this gap, comparing lorlatinib, alectinib, and brigatinib in ALK inhibitor-naive and untreated ALK-positive advanced NSCLC, but direct head-to-head trials are needed to solidify these findings that could obviate the need for certain treatment modalities and guide therapeutic management options [9]. Here, ALK is linked to non-small cell lung carcinoma.